Hormonal
Tirzepatide demonstrates cardiovascular safety, with hazard ratios for major adverse cardiovascular events (MACE) remaining below 1.3 compared to pooled comparators, indicating no increased cardiovascular risk.
For patients with heart disease or high risk factors, Tirzepatide has been shown to be safe regarding cardiovascular events. It does not increase the risk of heart attack, stroke, or cardiovascular death compared to standard treatments. This makes it a viable option for those who need effective diabetes management without compromising heart health.
For none of the cardiovascular events analysed (MACE-4, or its components) was a hazard ratio > 1.0 vs. pooled comparators found in a meta-analysis covering the whole clinical trial program, and the upper bounds of the confidence intervals for MACE were < 1.3, fulfilling conventional definitions of cardiovascular safety.
Why this rating
Based on pooled analysis of Phase 2 and 3 trials (SURPASS program), though the dedicated CVOT (SURPASS-CVOT) was ongoing at the time of publication.
Source
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Michael A. Nauck et al. · Cardiovascular Diabetology · 2022
DOI 10.1186/s12933-022-01604-7
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →